Pityriasis rosea: herald patch, Christmas-tree rash, and syphilis serology

What pityriasis rosea is — and why it matters beyond the rash

Pityriasis rosea is an acute, self-limited skin condition that resolves on its own without treatment in most adults and children. It follows a distinctive two-stage course: a single large “herald patch” appears first, followed one to two weeks later by a widespread eruption of smaller scaly plaques that forms a characteristic Christmas-tree pattern across the back. The whole eruption typically clears within six to eight weeks, leaving no permanent scarring.

The most likely cause is reactivation of two common herpes-family viruses — HHV-6 and HHV-7 — that most people acquire silently in childhood. This viral reactivation model, proposed by Drago and colleagues in 1997 and supported by subsequent studies detecting viral DNA in skin and blood, explains why the condition tends to cluster in spring and autumn, why it’s rare to get it twice (immune memory), and why it’s not contagious to household contacts in any meaningful way.

What makes pityriasis rosea clinically important in Australian general practice is the differential diagnosis. The rash of secondary syphilis can be essentially indistinguishable from pityriasis rosea. The two conditions look alike, occur at similar ages, and involve the trunk in similar distributions. Syphilis is rising in Australia — rates have been climbing particularly among women of reproductive age, where the consequences of a missed diagnosis extend to congenital infection in a future pregnancy. A syphilis blood test is therefore a mandatory, non-negotiable part of assessing any adolescent or adult with this rash, regardless of perceived risk or clinical confidence in the diagnosis.

A. Core clinical — the AU general-practice framework

Recognising the rash

The herald patch is usually the first sign: a single oval erythematous scaly plaque, typically 3–10 cm in diameter, on the trunk, proximal arm, or neck. It often has a slightly raised, scaly border with central clearing and resembles a patch of ringworm (tinea corporis), which is why it is sometimes mistakenly treated with antifungal cream at this stage. A skin scraping for fungal microscopy (KOH preparation) at this single-lesion stage rules out tinea corporis.

One to two weeks later the secondary eruption appears: dozens of smaller oval scaly plaques (0.5–2 cm), salmon-pink to red, appearing on the trunk and proximal limbs. Each lesion has a characteristic “collarette of scale” — fine scale that points inward toward the centre of the lesion. On the back, the long axes of the plaques follow the skin’s natural cleavage lines (Langer’s lines), producing the classic Christmas-tree or fir-tree pattern when viewed from behind. The face, distal limbs, palms, and soles are typically spared — involvement of palms or soles should raise the suspicion for syphilis.

Mild to moderate itch is present in about half of people. In people with darker skin tones (Fitzpatrick types IV–VI), the rash may appear less red and more brownish, and post-inflammatory hyperpigmentation or hypopigmentation can persist for several months after the eruption clears.

Mandatory investigations

Per Australian STI Management Guidelines and RACGP guidance on syphilis, the following investigations are required for every adolescent and adult:

• Syphilis serology: RPR (or VDRL) plus treponemal test (TPHA/TPPA/EIA) — mandatory regardless of sexual history, relationship status, or clinical confidence in the pityriasis rosea diagnosis. The rash of secondary syphilis is the classical mimic; absence of symptoms such as genital sores, swollen glands, or palm/sole involvement does not exclude syphilis — serology is the only way to exclude it. If syphilis is confirmed, it is a notifiable condition in all Australian states and territories, and contact tracing and treatment are required.
• HIV serology — recommended when there is any sexual or injecting drug use risk, as HIV seroconversion can also produce a morbilliform rash.
• Beta-hCG (pregnancy test) — in any woman of reproductive age before proceeding with further investigations or management.
• KOH microscopy / fungal scraping — at the single herald patch stage if tinea corporis is in the differential.

Skin biopsy is rarely needed and is reserved for atypical, prolonged (more than three months), or diagnostically uncertain cases.

Clinical management

Per Therapeutic Guidelines (eTG) and the Australasian College of Dermatologists, management is primarily supportive:

• Reassurance is the most important intervention. Understanding the natural history — that the rash will resolve by itself over six to eight weeks, that it is not contagious, and that it almost never recurs — significantly reduces patient anxiety.
• Emollient (moisturiser) — apply regularly to reduce dryness and the itch-scratch-irritation cycle; choose fragrance-free, non-irritant formulas.
• Topical low-potency corticosteroid — hydrocortisone 1% cream twice daily for one to two weeks reduces itch. If itch is more troublesome, a mid-potency agent (methylprednisolone aceponate 0.1%) may be appropriate for short periods.
• Oral antihistamine — a non-sedating antihistamine (cetirizine, loratadine, fexofenadine) during the day; a sedating antihistamine at night if sleep is disrupted. Per AMH, standard adult dosing applies.
• Avoid triggers that worsen itch: hot water bathing, harsh soaps, fragranced products, and wool or synthetic fibres in contact with the rash.
• Short sensible sun exposure — there is anecdotal and small-study evidence that natural UV exposure may ease itch and modestly speed resolution, consistent with the historical observation that pityriasis rosea tends to improve with sunlight. This is reasonable for short periods in Australian summers, but sunburn worsens the rash and carries skin cancer risk, so the usual sun-protection advice applies outside brief therapeutic exposure.

B. Evidence appraisal — aetiology, antiviral treatment, and phototherapy

The HHV-6/HHV-7 model

The viral reactivation hypothesis is the best-supported model for pityriasis rosea. Drago and colleagues (1997) demonstrated HHV-6 and HHV-7 DNA in plasma and peripheral blood mononuclear cells of patients with active pityriasis rosea, and multiple subsequent independent groups have reported similar findings in skin biopsy specimens. The spring-autumn clustering of cases is consistent with seasonal immune modulation facilitating viral reactivation, analogous to other HHV-family reactivation syndromes.

Not all studies have replicated positive viral detection, and the condition is not yet proven to be caused exclusively by these viruses, but no competing aetiology has stronger evidence. Clinically, the viral model explains the low rate of recurrence (approximately 3% lifetime), the non-contagious nature to household contacts, and the rare prodrome of mild fever and malaise before the herald patch.

Oral antiviral therapy

A 2018 meta-analysis by Singh and colleagues (JAMA Dermatology) found that oral aciclovir or valaciclovir, when started within the first week of the eruption’s onset, was associated with modest acceleration of resolution and reduction in itch severity. This is biologically plausible given the HHV aetiology. However, this is off-label use in Australia — the PBS subsidises these antivirals for herpes zoster, genital herpes, and varicella, but not for pityriasis rosea, which would require a private prescription. Given the self-limited and generally mild nature of pityriasis rosea, oral antivirals are not standard care; they may be considered by a GP or dermatologist for severe, extensive, or significantly distressing disease, or in the pregnancy context after specialist input.

Narrowband UVB phototherapy

For severe itch or extensive disease that has not responded to topical treatment and antihistamines, narrowband UVB phototherapy reduces itch and may shorten disease duration, per the Cochrane review by Chuh and colleagues (2007). This requires a referral to a dermatologist with phototherapy access and is not first-line general practice management.

C. Drug-induced pityriasis-rosea-like eruptions

A clinically and histologically similar eruption can be triggered by medications, and distinguishing drug-induced PR-like eruption from true pityriasis rosea influences management — removing the causative drug is the primary treatment for the drug-induced form.

Commonly implicated medications include:

• ACE inhibitors (especially captopril)
• NSAIDs (including ibuprofen and naproxen)
• Antimicrobials (terbinafine, metronidazole)
• Biologics (anti-TNF agents, IL-17 inhibitors)
• Vaccines — documented associations include BCG, hepatitis B, influenza, and COVID-19 vaccines (both mRNA and adenoviral vector formulations), with cases reported in the dermatological literature during the pandemic period

Drug-induced eruptions tend to be more pruritic, less classically patterned, and temporally linked to a recent medication or vaccine. The key discriminator is a careful medication and vaccination history taken in the two to eight weeks prior to eruption onset. Syphilis serology remains mandatory regardless. If a drug aetiology is suspected, the GP should review whether stopping or switching the medication is appropriate in the clinical context.

D. Australian operations

Most pityriasis rosea is assessed and managed in Australian general practice without specialist input. Standard consultation MBS items apply (Level B item 23, Level C item 36, Level D item 44). Telehealth consultation may be appropriate for follow-up in an established patient, but an initial presentation with diagnostic uncertainty usually benefits from in-person assessment, including direct skin inspection.

Pathology: syphilis serology is bulk-billable under current MBS pathology items. HIV serology, quantitative beta-hCG (serum), and fungal microscopy/culture are similarly MBS-covered. A skin biopsy (punch or shave) would be claimed under relevant surgical MBS items and pathology histopathology items.

PBS medicines: hydrocortisone 1% cream is available on the PBS General Schedule and also over the counter. Antihistamines (cetirizine, loratadine, fexofenadine) are available on the General Schedule or over the counter. Mid-potency corticosteroids (methylprednisolone aceponate) are on the General Schedule. Aciclovir and valaciclovir are PBS-listed for zoster and genital herpes but not for pityriasis rosea, where they would require a private prescription.

Notification: pityriasis rosea itself is not a notifiable condition. If syphilis is confirmed on screening serology, it is notifiable in all Australian states and territories under the National Notifiable Diseases Surveillance System. Similarly, confirmed HIV is notifiable. Notification is the GP’s responsibility; the state public health unit will advise on partner notification processes.

E. Special populations

Pregnancy. This is the highest-stakes scenario in pityriasis rosea. Drago and colleagues (Obstet Gynecol 2008) reported a significantly elevated rate of fetal demise and preterm birth in pregnant women with pityriasis rosea, with the risk appearing highest when the eruption was diagnosed at or before 15 weeks gestation. The proposed mechanism is active HHV-6 viraemia with placental transmission. The signal has not been uniformly replicated across all subsequent cohorts, so it should be discussed with appropriate uncertainty — but it is sufficient to require urgent dermatology and obstetric referral, serial fetal monitoring via ultrasound, and documented counselling. For pregnant women: topical hydrocortisone is generally considered safe; loratadine and cetirizine are used in pregnancy, ideally after discussion with the obstetric team. Aciclovir is TGA pregnancy category B3; its use in pityriasis rosea during pregnancy is an obstetric and dermatology decision only.

Darker skin tones (Fitzpatrick IV–VI). The rash may be less visibly erythematous and more difficult to recognise clinically, particularly the herald patch. Post-inflammatory hyperpigmentation or hypopigmentation is very common and can persist for several months after the rash has fully resolved. Patients with darker skin tones should be counselled that these pigment changes are temporary, that moisturising and gentle sun protection support natural recovery, and that the skin’s colour will return to baseline over months.

Children. Pityriasis rosea can occur in children, though it is less common than in young adults. In younger children, the eruption is more likely to be vesicular or papular rather than classically squamous. Mandatory syphilis serology applies to children in the same context as sexually active adolescents, but the clinical threshold for syphilis concern is lower in young children; the differential tilts more toward viral exanthems and guttate psoriasis in this age group. Paediatric pityriasis rosea is otherwise managed identically to adults.

When to escalate

Refer to a dermatologist when:

• The rash is atypical or diagnostically uncertain — asymmetric, involving only the face or genitals, or not following the classical pattern
• The rash persists beyond three months — requires biopsy to exclude pityriasis lichenoides chronica, mycosis fungoides, or another diagnosis
• Severe itch is unresponsive to topical corticosteroid and oral antihistamines — dermatologist can consider phototherapy, oral antiviral, or other options
• Drug-induced eruption with a medication that is not straightforward to stop
• Pregnancy — as above, urgent referral
• Confirmed syphilis — refer to a sexual health clinic for treatment, partner notification support, and follow-up serology

What this article is and is not

This article is general health information drawn from current Australian clinical guidelines — Therapeutic Guidelines (eTG), AMH, the Australasian College of Dermatologists, and Australian STI Management Guidelines — and key peer-reviewed studies. It is not personal medical advice and does not create a doctor–patient relationship. Diagnosis and treatment decisions are made with your own GP and treating clinicians, who can examine you, order and interpret investigations, and tailor management to your specific circumstances.

For Australian consumer resources: HealthDirect — pityriasis rosea, Australasian College of Dermatologists A–Z, Better Health Channel.

For syphilis concerns: contact your GP or a sexual health clinic. Testing is confidential, bulk-billable, and quick.

---

Sources cited

1. Drago F et al. — HHV-6/7 in pityriasis rosea (Dermatology 1997)
2. Drago F et al. — Pityriasis rosea in pregnancy (Obstet Gynecol 2008)
3. Singh A et al. — Antiviral therapy for pityriasis rosea meta-analysis (JAMA Dermatol 2018)
4. Chuh A et al. — Interventions for pityriasis rosea (Cochrane 2007)
5. Therapeutic Guidelines (eTG) — Dermatology
6. Australasian College of Dermatologists — Pityriasis rosea
7. Australian STI Management Guidelines — Syphilis
8. RACGP AJGP — Syphilis in general practice (2020)
9. Australian Medicines Handbook
10. TGA — Medicines in pregnancy database
11. National Notifiable Diseases Surveillance System
12. HealthDirect — Pityriasis rosea
13. Better Health Channel